Skip to main content

Advertisement

Figure 1 | Journal of Neuroinflammation

Figure 1

From: Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB1receptors

Figure 1

Anandamide inhibits VCAM-1 production induced by TMEV through a mechanism that involves CB 1 receptor. (A) sVCAM-1 levels were measured by ELISA in supernatants of cell cultures 20 h after AEA treatment (100 nM, 500 nM, 1 μM, 5 μM, 10 μM). Confluent TMEV-infected brain endothelial cell monolayers were pretreated for 1 hour before AEA treatment with (B) the cannabinoid receptor antagonist SR1 (1 μM) or AM630 (1 μM); (C) the vanilloid receptor antagonist capsazepine (10 μM); (D) the PPARγ receptor antagonist GW9662 (100 nM and 1 μM). Results show the means ± SEM from three independent experiments done in triplicate. (**p < 0,01 vs. vehicle; ##p < 0.01 vs. TMEV+vehicle; ++p < 0.01 vs. TMEV+AEA, ANOVA followed by Tuckey's test).

Back to article page